ByErin T. Welsh, MA
ByMichael Monostra
ByJill Rollet
Recent shortages of the type 2 diabetes therapies semaglutide and tirzepatide, widely reported in the consumer press, appear to be resolving, according to manufacturers and prescribers.
Beginning in the middle of last year in the United States, but extending globally, the shortages caused numerous challenges for prescribers treating people with type 2 diabetes and with obesity. Read more in Healio.